NCT02069106撤回4 期
An 8-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Daily Pro-Omega LDL for Low-Density Lipoprotein Cholesterol and Triglyceride Reduction in Subjects With Mixed Hyperlipoproteinemia
Nordic Pharma, USA0 个研究点开始时间: 2014年2月1日最近更新:
适应症
干预措施
试验速览
- 阶段
- 4 期
- 状态
- 撤回
- 发起方
- 主要终点
- Low-density lipoprotein cholesterol (LDL-C)
研究概览
简要总结
Pro-Omega LDL reduces low-density lipoprotein cholesterol and triglycerides in subjects with mixed hyperlipoproteinemia.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Men or women, ≥18 years of age.
- •History (>3months) of LDL-C ≥130 mg/dl to ≤190 mg/dL
- •Triglycerides (TG) > 200 to <750 mg/dL
- •Able to understand and cooperate with study procedures, and have signed a written informed consent prior to any study procedures.
- •Willing to maintain a stable diet and level of activity throughout the trial. Willing to maintain current activity level and diet throughout the trial.
- •If, of childbearing age, must be on a medically approved form of birth control as identified by the investigator in this trial
- •History (> 3 months) of taking a statin medication (HMG-CoA reductase inhibitor, including Lipitor, Zocor, Crestor, Pravachol, Lescol, Livalo) without problems, and would be willing to withdraw from statin for the duration of the trial (4 weeks without statin prior to randomization for washout period, then treatment with protocol medication for 10 week duration of the trial)
排除标准
- •Individuals with intolerance of, or allergy to red yeast rice or omega 3 fatty acids.
- •Individuals currently taking a statin (HMG-CoA Reductase inhibitor) including Lipitor, Zocor, Crestor, Pravachol, Lescol, Livalo) or other lipid metabolism altering product within four (4) weeks prior to randomization who do not wish to withdraw from therapy.
- •Individual taking prescription or over the counter medications (including dietary supplements) known to alter lipid metabolism within four (4) weeks of randomization. Medications excluded within 4 weeks of randomization are: prescription omega-3 fatty acids, statins, bile acid sequestrants, cholesterol absorption inhibitors, niacin or fibrates. Dietary supplements excluded within 4 weeks prior to randomization are: L-carnitine, policosanol, guggulipid, sterol/stanol products, red rice yeast supplements, garlic supplements, soy isoflavone supplements, niacin or its analogues, probiotics and dietary fiber supplements (including >2 teaspoons Metamucil or psyllium-containing supplements per day and prebiotics), or any dietary supplement or vitamin complex product containing omega 3 acids or fish oil.
- •Use of systemic corticosteroids, androgens (except androgens for hypogonadism to restore normal levels), phenytoin, erythromycin and other macrolides, and thyroid hormones (except stable-dose thyroid replacement therapy for four (4) weeks prior to enrollment).
- •Use of the anticoagulants warfarin (Coumadin) or dabigatran (Pradaxa), apixaban (Eliquis) or rivaroxaban (Xarelto).
- •Pregnant or lactating women, or women of childbearing potential who are not complying with an approved method of contraception. A woman is considered to be of childbearing potential unless she is post-hysterectomy, one or more years postmenopausal, or one or more years post-tubal ligation.
- •Individuals with a history of myopathy, defined as a creatine phosphokinase (CPK) >450 U/L and/or unexplained muscle pain on statins.
- •Type I or type II diabetes mellitus or HbA1c ≥7.0%
- •History of significant cardiovascular or coronary heart disease (CVD or CHD) as defined by having had a coronary artery bypass procedure, coronary stent or angioplasty, or myocardial infarction.
- •Current or recent (within six months) history of significant gastrointestinal, renal, pulmonary, hepatic or biliary disease
- •History of cancer, other than non-melanoma skin cancer and basal cell carcinoma, within the previous five years.
- •Poorly controlled or uncontrolled hypertension (systolic blood pressure ≥160 mm Hg and/or diastolic blood pressure ≥95 mm Hg).
- •Recent history (within past 6 months) of excessive alcohol use, defined as >14 drinks per week (One drink = 12 oz. beer, 4 oz. wine, 1.5 oz. hard liquor).
- •Exposure to any investigational agent within 4 weeks prior to Visit
- •Has a condition the Investigator believes would interfere with the evaluation of the subject, or may put the subject at undue risk during the course of the study.
研究组 & 干预措施
Pro-Omega LDL
Experimental
3 capsules 1000 mg BID for 8 weeks
干预措施: Pro-Omega LDL (Dietary Supplement)
Placebo
Placebo Comparator
3 capsules BID for 8 weeks
干预措施: Placebo (Other)
结局指标
主要结局
Low-density lipoprotein cholesterol (LDL-C)
时间窗: 8 weeks
Triglycerides (TG)
时间窗: 8 weeks
次要结局
- Adverse events(4 and 8 weeks)
- LDL-C/HDL-C ratio(8 weeks)
- C-reactive protein(8 weeks)
- Total cholesterol(8 weeks)
- High-density lipoprotein cholesterol (HDL-C)(8 weeks)
- non-HDL-C(8 weeks)
- Offset effect(2 weeks after withdrawal)
研究者
相似试验
已完成
3 期
Evaluation of Alirocumab in Addition to Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia in South Korea and TaiwanHypercholesterolemiaNCT02289963Sanofi199
已完成
3 期
Phase III Study To Evaluate Alirocumab in Patients With Hypercholesterolemia Not Treated With a Statin (ODYSSEY CHOICE II)HypercholesterolemiaNCT02023879Sanofi233
已完成
3 期
Evaluation of Alirocumab Versus Ezetimibe on Top of Statin in Asia in High Cardiovascular Risk Patients With HypercholesterolemiaHypercholesterolemiaNCT02715726Sanofi615
已完成
3 期
Efficacy and Safety Evaluation of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia or High Cardiovascular Risk Patients With Hypercholesterolemia on Lipid Modifying Therapy (ODYSSEY JAPAN)HypercholesterolemiaNCT02107898Sanofi216
已完成
3 期
Efficacy and Safety of Alirocumab in Patients With Hypercholesterolemia Not Adequately Controlled With Non-statin Lipid Modifying Therapy or the Lowest Strength of StatinHypercholesterolemiaNCT02584504Sanofi163